预测抗甲状腺药物治疗Graves病复发的分子标志物

Molecular markers for predicting Graves' disease recurrence treated with antithyroid drugs

抗甲状腺药物(ATD)治疗Graves病(GD)有较高的复发率,寻找可以判断ATD治疗GD预后的标志物十分重要。近来,核酸分子标志物,如单核苷酸基因多态性(SNP)和微小RNA(microRNAs)以及代谢组学标志物等分子标志物逐渐被用于GD的诊断和预后评估。其中,SNP在预测ATD治疗GD的缓解或复发中有较大价值。明确上述小分子物质与ATD治疗后GD复发的相关性,有助于寻找新的影响GD预后的因素,为治疗决策提供更精准的指导。本文对新型分子标志物在GD复发风险预测中的价值和未来研究方向做一综述。

In view of the high recurrence rate of Graves' disease(GD)treated with antithyroid drugs(ATD),it is very important to find suitable markers with prognostic value for ATD treatment of GD.Recently,nucleic acid markers,such as single nucleotide polymorphism(SNP),microRNAs and metabolomics parameters,have been gradually used in the diagnosis and prognosis assessment of GD.Among them,SNP is of great value in predicting the remission or recurrence of GD treated with ATD.Clarifying the relationship between the above small molecules substances and the recurrence of GD after ATD treatment is helpful to find out the new factors affecting the prognosis of GD,and provide more precise guidance for treatment decision-making.This paper reviews the research on the value of new molecular markers in the prediction of GD recurrence risk and the future research direction.